<DOC>
	<DOCNO>NCT01156090</DOCNO>
	<brief_summary>The purpose study identify approximately 100 - 150 patient receive Vectibix ( Panitumumab ) office clinic locate Tennessee , North Carolina , South Carolina , North Georgia February 2004 - April 2009 . Information regard incidence severity hypersensitivity infusion reaction Vectibix ( Panitumumab ) capture . In patient experienced hypersensitivity reaction , follow information also collect : premedication , treatment cycle symptom experience chemotherapy , change require subsequent Vectibix ( Panitumumab ) chemotherapy treatment , outcome hypersensitivity reaction .</brief_summary>
	<brief_title>A Retrospective Cohort Study Infusion Reactions Due Vectibix</brief_title>
	<detailed_description />
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion Criteria All patient treat least one treatment Vectibix ( Panitumumab ) February 2004 April 2009 eligible study . Patients may may infusion reaction Vectibix ( Panitumumab ) . Major infusion reaction define rapid onset airway obstruction ( bronchospasm , stridor , hoarseness ) , urticaria , erythema , and/or hypotension , anaphylaxis . Minor infusion reaction define transient flushing rash , urticaria , dyspnea , drug fever . Patients receive treatment EGFR past eligible . Exclusion Criteria There exclusion base age , sex , medical history , use concomitant therapy . All chart abstract information , completion last chemotherapy cycle .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>vectibix</keyword>
</DOC>